Most patients in whom prostate cancer is suspected are identified on the basis of raised PSA (prostate specific antigen) levels or abnormal findings during digital rectal examination (DRE), but DRE has little value as a screening test. The positive predictive value of DRE was 18 and 28% in 2 meta-analyses [1, 2] . PSA is a serine protease produced by prostate epithelial cells and secreted into seminal fluid. PSA was first detected in serum in 1979, and in the late 1980s it became widely used to screen for prostate cancer. Both malignant and normal prostate cells secrete this enzyme, but when a cancer disrupts the gland's architecture, the levels in the systemic circulation often rise. The traditional cut-off indicating suspicion for cancer, and indication for biopsy, has been >4 ng/ml. At this cut-off point, most studies report sensitivity for cancer of around 70%, with more variability in specificity [1, [3] [4] [5] . Oesterling [6] initially suggested that the PSA cut-off for biopsies should change based on age, with 2.5 ng/ml for men aged 40-49, 3.5 ng/ml for 50-to 59-year-olds, 4.5 ng/ml for 60-to 69-year-olds, and 6.5 ng/ml for 70-to 79-year-olds.
From 800 prostate cancer patients treated in our institution, only 13 (1.6%) are Bedouins. The purpose of the study was to see whether only the awareness of prostate cancer within Bedouin men is low or whether the incidence of prostate cancer is truly low among the Bedouin population.
Patients and Methods
The subjects in this study came from a geographically defined population from the Negev desert surrounding Beer Sheva and include 206 men aged ≥50 out of 1,221 male inhabitants. The median age at prostate cancer screening was 64 years (range 50-96). Total PSA tests were performed in all patients. Patients with abnormal PSA levels were scheduled for DRE, trans-rectal ultrasound (TRUS), and ultrasound-guided biopsy of the prostate.
Results
The average PSA level was 1.67 ng/ml (range 0.07-22.1). The distribution of the patients by age and PSA level at screening is represented in table 1. Abnormal PSA levels were present in 13 out of 206 subjects. Only 10 of these agreed to have TRUS and biopsy. 3 patients refused investigation by DRE and TRUS. The average number of biopsies was 8 (range 6-10). Prostate cancer was not confirmed. The histological diagnosis was benign prostatic hyperplasia (BPH) or chronic inflammation.
Discussion
Internationally, prostate cancer is the second most common cancer diagnosed among men and the sixth most common cause of death from cancer among men. Prostate cancer is particularly prevalent in developed countries such as the United States and the Scandinavian countries, with about a 6-fold difference between high-incidence and low-incidence regions [7] .
The incidence of clinical prostate cancer in the Arab population is low. Prostate cancer was found in only 1.17% of Saudi men participating in the screening program of the Outpatient Department at King Fahd Hospital of King Faisal University, Al-Khobar, Kingdom of Saudi Arabia [8] .
Bedouins are an ethnic minority of the Muslim minority in Israel. The Bedouins in the Negev originate from the Hejaz, a region in the north of the Arabian Peninsula. The basic unit of Bedouin social organization is the tribe. The population taking part in screening originates from 3 tribes. Roughly 54% of the Bedouin population is <14 years old, which accounts for the low number (206 out of 1,221) of the screened population. The majority of the Bedouins relies on agriculture for subsistence, and the educational level is low in comparison with the general population.
One of the possible causes of low incidence of prostate cancer among Arab men are lower serum insulin-like growth factor 1 (IGF-1) levels compared to Caucasians [9] . Another possible cause is the healing potential of medicinal plants, based on a rational analysis of an ethnopharmacological field survey among Bedouins in the Negev desert [10] . The Palestinian mountains are rich in plant species. 59 plants, which include Arum dioscorides, Urtica pilulifera, Allium sativum, Viscum cruciatum, and Allium cepa, are claimed to be effective against cancer and prostate disorders [11] . This is in agreement with similar findings on the status of medicinal plants among Bedouins in the Negev desert.
The possible effect of PSA screening in asymptomatic men remains controversial despite the test's widespread application. The continued controversy regarding PSA screening relates to the potential overdiagnosis of localized prostate cancers that are not likely to become clinically significant [4] .
Screening can detect prostate cancer in 4 groups of men. Firstly, those whose cancer emerges clinically, whose outcome is not affected by being treated at that time, and for whom screening would not affect their situation. Secondly, those whose cancer is advancing so rapidly that screening would not improve their outcome. Thirdly, those whose screen-detected disease would otherwise never have manifested itself and who are exposed to unnecessary treatment. Fourthly, asymptomatic individuals who receive beneficial treatment that would Abdallah/Lazarev/Ariad/Mermershtain have been denied otherwise. The difficulty in identifying this 4th group, who will actually benefit from screening, renders the current case for screening very weak. However, as the capacity to identify men in this 4th group increases, the case will strengthen accordingly [12, 13] .
In conclusion, the Bedouin men from a geographically defined population from the Negev desert surrounding Beer Sheva have low PSA serum concentration. The incidence rate of prostate cancer is very low and screening is not justified in the asymptomatic Bedouin population.
